The challenge addressed by the NT210 plus cetuximab combination—overcoming acquired resistance to EGFR blockade—reflects a central theme in HNSCC research, as EGFR is overexpressed in 80% to 100% of cases [87]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.